Respiratory Diseases

FDA Grants Priority Review to Pfizer’s RSV Vaccine Candidate for Older Americans
December 08, 2022

The FDA has granted priority review to a biologics license application for Pfizer’s respiratory syncytial virus vaccine candidate, RSVpreF, for adults aged ≥60 years.

7 RSV Myths and Facts: Prepare for the New Wave of Misinformation
November 03, 2022

RSV is back for the 2022-23 respiratory virus season and is unfamiliar to many. Click through this quick collection of myths already in circulation to prepare.

RSV Older Adult Vaccine Candidate from GSK Wins FDA Priority Review, PDUFA Date Set
November 02, 2022

The FDA accepted the GSK BLA and granted priority review to what could be the first vaccine approved against RSV in adults aged ≥60 years, according to the company.

Maternal RSV Vaccine Prevents Infection in Infants, Pfizer Announces
November 02, 2022

Topline phase 3 trial data showed 81.8% efficacy for the maternal vaccine against severe RSV-related illness in infants from birth through first 90 days of life.

Adult RSV Vaxx Gets EMA Nod: Can USA be Far Behind?
October 28, 2022

The GSK RSV vaccine candidate has received favorable international regulatory attention which may be an auspicious sign for the US.

Daily Dose: Delay Before Start of Triple Therapy Raises Risk for COPD Exacerbations
October 24, 2022

Your daily dose of clinical news you may have missed.

Fluticasone Exhalation Delivery System Reduced Exacerbations, Need for Antibiotics in Patients with Chronic Sinusitis
October 24, 2022

IDWeek 2022: New data show a greater than 60% reduction in acute exacerbations and need for antibiotics in patients with CS who used fluticasone propionate nasal spray.

High-dose Influenza Vaccine Consistently More Effective vs Standard-dose in Older Adults: Meta-analysis
October 24, 2022

The high-dose influenza vaccines provided greater relative vaccine effectiveness/efficacy vs standard dose in a cohort of more than 45 million.

COPD: Delay Before Start of Triple Therapy May Increase Risk for Exacerbations
October 21, 2022

CHEST. After a moderate COPD event, treatment with TT within 30 days significantly reduced risk for exacerbation over 12 months vs treatment after 30 days.